Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

NCT05257408 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT05257408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 29, 2022
Completion date
December 31, 2026
Enrollment
381 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian neoplasm, peritoneal neoplasms